Premium
Long‐term results of adjuvant gemcitabine plus S‐1 chemotherapy after surgical resection for pancreatic carcinoma
Author(s) -
Murakami Yoshiaki,
Uemura Kenichiro,
Sudo Takeshi,
Hashimoto Yasushi,
Nakashima Akira,
Kondo Naru,
Nakagawa Naoya,
Sueda Taijiro
Publication year - 2012
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23068
Subject(s) - medicine , gemcitabine , chemotherapy , regimen , surgery , adjuvant , carcinoma , oncology , gastroenterology
Background and Objectives This study evaluated long‐term outcomes for patients who received adjuvant gemcitabine plus S‐1 chemotherapy after resection for pancreatic carcinoma. Methods Seventy patients who underwent surgical resection of pancreatic carcinoma were enrolled prospectively into this study. All patients received adjuvant chemotherapy with 10 cycles of gemcitabine plus S‐1 every 2 weeks. Each cycle consisted of intravenous gemcitabine 700 mg/m 2 on day 1 and oral S‐1 50 mg/m 2 for seven consecutive days, followed by a 1‐week pause of chemotherapy. Long‐term survival results of adjuvant gemcitabine plus S‐1 chemotherapy were analyzed for this cohort. Results Median follow‐up time was 51.2 months. Sixty percent of patients had node‐positive disease and 79% of patients underwent R0 resection. Fifty‐six patients (80%) completed adjuvant chemotherapy. Median overall and disease‐free survival times were 35.4 and 23.8 months, respectively. Actuarial overall and disease‐free survival rates were 89% and 64% at 1 year, 64% and 50% at 2 years, and 33% and 33% at 5 years, respectively. Only negative lymph node metastasis ( P = 0.010) independently correlated with long‐term survival by multivariate analysis. Conclusions Long‐term results of adjuvant gemcitabine plus S‐1 chemotherapy suggest this regimen may be safe and promising as treatment for this patient population. J. Surg. Oncol. 2012; 106:174–180. © 2012 Wiley Periodicals, Inc.